MGI Tech Unveils its SEQ ALL landscape at the Future of Omics Conference
9/10/24
9/13/24
Offline
Shenzhen, China
Share
The Future of Omics conference, hosted by MGI, was a groundbreaking four-day event that brought together experts from around the world to explore advancements in life sciences. The conference began with an exclusive satellite event at MGI’s cutting-edge αLab in Hong Kong, followed by sessions at the company’s state-of-the-art global headquarters in Shenzhen, China. Attendees experienced a dynamic program featuring keynote speeches, the latest technology updates, product demonstrations, and an Eco-partner showcase. Renowned global leaders in the field shared insights, with a special focus on the transformative potential of omics technologies.
“We are thrilled to bring together some of the world’s leading life science researchers, academics, clinicians, and collaborators to exchange valuable insights,” said Duncan Yu, President of MGI, during his opening remarks. “Throughout our 8-year journey, innovation has been central to MGI. We continually strive to deliver cutting-edge technology that empowers diverse applications and expands multi-omics capabilities, unlocking new possibilities. We look forward to inspiring innovation and driving exciting developments in the future of omics.”
Sequencing Capabilities to Provide “SEQ ALL”
Dr. Rade Drmanac, Chief Scientific Officer of MGI, introduced the term “SEQ ALL” during his presentation, referring to MGI’s comprehensive capacity to offer a wide range of sequencing applications to meet diverse user needs.
“MGI provides a complete DCS lab for DNA, cell, and spatial omics. Together, these technologies define a new generation of MPS (MPS 2.0) and set a new standard in WGS (CompleteWGS). MGI is the only company offering the SEQ ALL portfolio, supporting all sequencing applications. MGI has it all.”
Powered by its advanced massively parallel sequencing (MPS) technology, DNBSEQ™, with key advantages in efficiency, accuracy, and cost-effectiveness, MGI offers T Series, G Series, and E Series genetic sequencers, with data throughput ranging from GB to TB, serving diverse user needs and scenarios. Earlier this year, MGI launched the Standard MPS 2.0 (SM2.0) upgrade for its DNBSEQ™ platforms, improving sequencing quality with an increased percentage of Q40 bases.
By leveraging its robust suite of technologies, MGI strengthens its position as a leading life sciences technology provider, offering versatile sequencing throughputs and read lengths, short-read and long-read sequencing, single-cell omics, and spatial omics—all under its “SEQ ALL” approach.
Expanding Multi-Omics Access Globally
Providing highly efficient whole workflow solutions for DNA omics, cell omics, spatial omics, and multi-omics, MGI is dedicated to empowering omics research to tackle complex biological challenges.
Multi-Omics
Last year, MGI launched the DCS Lab Initiative to facilitate global access to multi-omics capabilities. At the conference, MGI announced the successful establishment of 10 DCS labs across China, Germany, and Singapore, leveraging its unique ability to provide end-to-end solutions for both research and clinical translational applications.
MGI also launched DNBSEQ-G400RS FluoXpert, a multi-functional sequencer compatible with in vivo spatial protein detection. It supports a wide range of applications, including tumor classification, disease prognosis, and tissue microenvironment analysis.
Spatial Omics
As part of its commitment to providing users with the most accessible, comprehensive, and efficient spatial-temporal omics workflow solutions, MGI became an official distributor of a selection of STOmics-related products in July of this year. The Stereo-seq libraries are sequenced on MGI’s flagship DNBSEQ-G400RS and DNBSEQ-T7RS platforms, ensuring high-quality data output.
At the Future of Omics Conference, MGI introduced Stereo-seq Transcriptomics Solution v1.3 (Stereo-seq v1.3), an upgraded STOmics solution designed for fresh frozen samples. This version significantly improves the capture efficiency of whole transcriptome information at true single-cell resolution. The product is available for ordering starting in September. Previously, Stereo-seq OMNI, a revolutionary sequencing-based spatial transcriptomics solution compatible with multiple species, was released. Stereo-seq OMNI allows users to obtain spatial total RNA information from FFPE samples at single-cell resolution, diving deeper into molecular changes in precious clinical samples. Through its innovative "Random Probe" design, both total RNA and microbiome information can be detected on the same tissue slide.
Cell Omics
For cell omics, MGI offers a comprehensive platform that includes DNBelab C Series for single-cell research, encompassing storage, transport, sample preparation, labeling, library preparation, high-throughput sequencing, and data analysis.
At the conference, MGI introduced the DNBelab C series High-Throughput Single-Cell 5' RNA & V(D)J Library Preparation Kit. This kit can be used with the DNBelab C-TaiM4, a droplet generator previously released, to complete the droplet encapsulation process within 12 minutes. Combined with the DNBC4Tools analysis tool, it can process up to 20,000 cells per slide per run, completing single-cell 5' RNA, TCR, and BCR library preparation and data quality control analysis.
End-to-End Solutions
MGI is uniquely positioned to leverage its suite of automation platforms to develop comprehensive solutions that optimize every step of the process, delivering more impactful results. MGI has introduced solutions like low-pass sequencing for agriculture, eDNA for public health, and a human microbiome metagenomics sequencing package to enhance efficiency, accuracy, and research turnaround times, enabling researchers to focus on results rather than labor-intensive tasks.
At the conference, MGI also launched solutions for PopGen Omics. Population genetics examines genetic differences within and among populations, which can lead to clearer insights into disease prevention, risk prediction, and diagnosis. MGI’s PopOmics Sequencing Package offers a unique perspective by combining genomics, epigenomics, transcriptomics, and metagenomics into a comprehensive individual readout.
Equipped with multi-omics capabilities, MGI continues to offer a broad product lineup and end-to-end workflows, driving innovation in clinical genomics, population genomics, public health, animal and plant genomics, environmental genomics, and other applications.
Over the next three days of the Future of Omics conference, more than 60 speakers and 10 ecosystem partners from around the world will present their cutting-edge innovations and advancements in the field of omics. Together, they will exchange insights and collaborate on shaping the breakthroughs of tomorrow.
MGI’s Future of Omics Conference runs from 10 to 13 September 2024 in Shenzhen and Hong Kong. For more information, please visit: https://futureofomics.com/
For research use only. Not for use in diagnostic procedures.
The Future of Omics conference, hosted by MGI, was a groundbreaking four-day event that brought together experts from around the world to explore advancements in life sciences. The conference began with an exclusive satellite event at MGI’s cutting-edge αLab in Hong Kong, followed by sessions at the company’s state-of-the-art global headquarters in Shenzhen, China. Attendees experienced a dynamic program featuring keynote speeches, the latest technology updates, product demonstrations, and an Eco-partner showcase. Renowned global leaders in the field shared insights, with a special focus on the transformative potential of omics technologies.
“We are thrilled to bring together some of the world’s leading life science researchers, academics, clinicians, and collaborators to exchange valuable insights,” said Duncan Yu, President of MGI, during his opening remarks. “Throughout our 8-year journey, innovation has been central to MGI. We continually strive to deliver cutting-edge technology that empowers diverse applications and expands multi-omics capabilities, unlocking new possibilities. We look forward to inspiring innovation and driving exciting developments in the future of omics.”
Sequencing Capabilities to Provide “SEQ ALL”
Dr. Rade Drmanac, Chief Scientific Officer of MGI, introduced the term “SEQ ALL” during his presentation, referring to MGI’s comprehensive capacity to offer a wide range of sequencing applications to meet diverse user needs.
“MGI provides a complete DCS lab for DNA, cell, and spatial omics. Together, these technologies define a new generation of MPS (MPS 2.0) and set a new standard in WGS (CompleteWGS). MGI is the only company offering the SEQ ALL portfolio, supporting all sequencing applications. MGI has it all.”
Powered by its advanced massively parallel sequencing (MPS) technology, DNBSEQ™, with key advantages in efficiency, accuracy, and cost-effectiveness, MGI offers T Series, G Series, and E Series genetic sequencers, with data throughput ranging from GB to TB, serving diverse user needs and scenarios. Earlier this year, MGI launched the Standard MPS 2.0 (SM2.0) upgrade for its DNBSEQ™ platforms, improving sequencing quality with an increased percentage of Q40 bases.
By leveraging its robust suite of technologies, MGI strengthens its position as a leading life sciences technology provider, offering versatile sequencing throughputs and read lengths, short-read and long-read sequencing, single-cell omics, and spatial omics—all under its “SEQ ALL” approach.
Expanding Multi-Omics Access Globally
Providing highly efficient whole workflow solutions for DNA omics, cell omics, spatial omics, and multi-omics, MGI is dedicated to empowering omics research to tackle complex biological challenges.
Multi-Omics
Last year, MGI launched the DCS Lab Initiative to facilitate global access to multi-omics capabilities. At the conference, MGI announced the successful establishment of 10 DCS labs across China, Germany, and Singapore, leveraging its unique ability to provide end-to-end solutions for both research and clinical translational applications.
MGI also launched DNBSEQ-G400RS FluoXpert, a multi-functional sequencer compatible with in vivo spatial protein detection. It supports a wide range of applications, including tumor classification, disease prognosis, and tissue microenvironment analysis.
Spatial Omics
As part of its commitment to providing users with the most accessible, comprehensive, and efficient spatial-temporal omics workflow solutions, MGI became an official distributor of a selection of STOmics-related products in July of this year. The Stereo-seq libraries are sequenced on MGI’s flagship DNBSEQ-G400RS and DNBSEQ-T7RS platforms, ensuring high-quality data output.
At the Future of Omics Conference, MGI introduced Stereo-seq Transcriptomics Solution v1.3 (Stereo-seq v1.3), an upgraded STOmics solution designed for fresh frozen samples. This version significantly improves the capture efficiency of whole transcriptome information at true single-cell resolution. The product is available for ordering starting in September. Previously, Stereo-seq OMNI, a revolutionary sequencing-based spatial transcriptomics solution compatible with multiple species, was released. Stereo-seq OMNI allows users to obtain spatial total RNA information from FFPE samples at single-cell resolution, diving deeper into molecular changes in precious clinical samples. Through its innovative "Random Probe" design, both total RNA and microbiome information can be detected on the same tissue slide.
Cell Omics
For cell omics, MGI offers a comprehensive platform that includes DNBelab C Series for single-cell research, encompassing storage, transport, sample preparation, labeling, library preparation, high-throughput sequencing, and data analysis.
At the conference, MGI introduced the DNBelab C series High-Throughput Single-Cell 5' RNA & V(D)J Library Preparation Kit. This kit can be used with the DNBelab C-TaiM4, a droplet generator previously released, to complete the droplet encapsulation process within 12 minutes. Combined with the DNBC4Tools analysis tool, it can process up to 20,000 cells per slide per run, completing single-cell 5' RNA, TCR, and BCR library preparation and data quality control analysis.
End-to-End Solutions
MGI is uniquely positioned to leverage its suite of automation platforms to develop comprehensive solutions that optimize every step of the process, delivering more impactful results. MGI has introduced solutions like low-pass sequencing for agriculture, eDNA for public health, and a human microbiome metagenomics sequencing package to enhance efficiency, accuracy, and research turnaround times, enabling researchers to focus on results rather than labor-intensive tasks.
At the conference, MGI also launched solutions for PopGen Omics. Population genetics examines genetic differences within and among populations, which can lead to clearer insights into disease prevention, risk prediction, and diagnosis. MGI’s PopOmics Sequencing Package offers a unique perspective by combining genomics, epigenomics, transcriptomics, and metagenomics into a comprehensive individual readout.
Equipped with multi-omics capabilities, MGI continues to offer a broad product lineup and end-to-end workflows, driving innovation in clinical genomics, population genomics, public health, animal and plant genomics, environmental genomics, and other applications.
Over the next three days of the Future of Omics conference, more than 60 speakers and 10 ecosystem partners from around the world will present their cutting-edge innovations and advancements in the field of omics. Together, they will exchange insights and collaborate on shaping the breakthroughs of tomorrow.
MGI’s Future of Omics Conference runs from 10 to 13 September 2024 in Shenzhen and Hong Kong. For more information, please visit: https://futureofomics.com/
For research use only. Not for use in diagnostic procedures.
The Future of Omics conference, hosted by MGI, was a groundbreaking four-day event that brought together experts from around the world to explore advancements in life sciences. The conference began with an exclusive satellite event at MGI’s cutting-edge αLab in Hong Kong, followed by sessions at the company’s state-of-the-art global headquarters in Shenzhen, China. Attendees experienced a dynamic program featuring keynote speeches, the latest technology updates, product demonstrations, and an Eco-partner showcase. Renowned global leaders in the field shared insights, with a special focus on the transformative potential of omics technologies.
“We are thrilled to bring together some of the world’s leading life science researchers, academics, clinicians, and collaborators to exchange valuable insights,” said Duncan Yu, President of MGI, during his opening remarks. “Throughout our 8-year journey, innovation has been central to MGI. We continually strive to deliver cutting-edge technology that empowers diverse applications and expands multi-omics capabilities, unlocking new possibilities. We look forward to inspiring innovation and driving exciting developments in the future of omics.”
Sequencing Capabilities to Provide “SEQ ALL”
Dr. Rade Drmanac, Chief Scientific Officer of MGI, introduced the term “SEQ ALL” during his presentation, referring to MGI’s comprehensive capacity to offer a wide range of sequencing applications to meet diverse user needs.
“MGI provides a complete DCS lab for DNA, cell, and spatial omics. Together, these technologies define a new generation of MPS (MPS 2.0) and set a new standard in WGS (CompleteWGS). MGI is the only company offering the SEQ ALL portfolio, supporting all sequencing applications. MGI has it all.”
Powered by its advanced massively parallel sequencing (MPS) technology, DNBSEQ™, with key advantages in efficiency, accuracy, and cost-effectiveness, MGI offers T Series, G Series, and E Series genetic sequencers, with data throughput ranging from GB to TB, serving diverse user needs and scenarios. Earlier this year, MGI launched the Standard MPS 2.0 (SM2.0) upgrade for its DNBSEQ™ platforms, improving sequencing quality with an increased percentage of Q40 bases.
By leveraging its robust suite of technologies, MGI strengthens its position as a leading life sciences technology provider, offering versatile sequencing throughputs and read lengths, short-read and long-read sequencing, single-cell omics, and spatial omics—all under its “SEQ ALL” approach.
Expanding Multi-Omics Access Globally
Providing highly efficient whole workflow solutions for DNA omics, cell omics, spatial omics, and multi-omics, MGI is dedicated to empowering omics research to tackle complex biological challenges.
Multi-Omics
Last year, MGI launched the DCS Lab Initiative to facilitate global access to multi-omics capabilities. At the conference, MGI announced the successful establishment of 10 DCS labs across China, Germany, and Singapore, leveraging its unique ability to provide end-to-end solutions for both research and clinical translational applications.
MGI also launched DNBSEQ-G400RS FluoXpert, a multi-functional sequencer compatible with in vivo spatial protein detection. It supports a wide range of applications, including tumor classification, disease prognosis, and tissue microenvironment analysis.
Spatial Omics
As part of its commitment to providing users with the most accessible, comprehensive, and efficient spatial-temporal omics workflow solutions, MGI became an official distributor of a selection of STOmics-related products in July of this year. The Stereo-seq libraries are sequenced on MGI’s flagship DNBSEQ-G400RS and DNBSEQ-T7RS platforms, ensuring high-quality data output.
At the Future of Omics Conference, MGI introduced Stereo-seq Transcriptomics Solution v1.3 (Stereo-seq v1.3), an upgraded STOmics solution designed for fresh frozen samples. This version significantly improves the capture efficiency of whole transcriptome information at true single-cell resolution. The product is available for ordering starting in September. Previously, Stereo-seq OMNI, a revolutionary sequencing-based spatial transcriptomics solution compatible with multiple species, was released. Stereo-seq OMNI allows users to obtain spatial total RNA information from FFPE samples at single-cell resolution, diving deeper into molecular changes in precious clinical samples. Through its innovative "Random Probe" design, both total RNA and microbiome information can be detected on the same tissue slide.
Cell Omics
For cell omics, MGI offers a comprehensive platform that includes DNBelab C Series for single-cell research, encompassing storage, transport, sample preparation, labeling, library preparation, high-throughput sequencing, and data analysis.
At the conference, MGI introduced the DNBelab C series High-Throughput Single-Cell 5' RNA & V(D)J Library Preparation Kit. This kit can be used with the DNBelab C-TaiM4, a droplet generator previously released, to complete the droplet encapsulation process within 12 minutes. Combined with the DNBC4Tools analysis tool, it can process up to 20,000 cells per slide per run, completing single-cell 5' RNA, TCR, and BCR library preparation and data quality control analysis.
End-to-End Solutions
MGI is uniquely positioned to leverage its suite of automation platforms to develop comprehensive solutions that optimize every step of the process, delivering more impactful results. MGI has introduced solutions like low-pass sequencing for agriculture, eDNA for public health, and a human microbiome metagenomics sequencing package to enhance efficiency, accuracy, and research turnaround times, enabling researchers to focus on results rather than labor-intensive tasks.
At the conference, MGI also launched solutions for PopGen Omics. Population genetics examines genetic differences within and among populations, which can lead to clearer insights into disease prevention, risk prediction, and diagnosis. MGI’s PopOmics Sequencing Package offers a unique perspective by combining genomics, epigenomics, transcriptomics, and metagenomics into a comprehensive individual readout.
Equipped with multi-omics capabilities, MGI continues to offer a broad product lineup and end-to-end workflows, driving innovation in clinical genomics, population genomics, public health, animal and plant genomics, environmental genomics, and other applications.
Over the next three days of the Future of Omics conference, more than 60 speakers and 10 ecosystem partners from around the world will present their cutting-edge innovations and advancements in the field of omics. Together, they will exchange insights and collaborate on shaping the breakthroughs of tomorrow.
MGI’s Future of Omics Conference runs from 10 to 13 September 2024 in Shenzhen and Hong Kong. For more information, please visit: https://futureofomics.com/
For research use only. Not for use in diagnostic procedures.
The Future of Omics conference, hosted by MGI, was a groundbreaking four-day event that brought together experts from around the world to explore advancements in life sciences. The conference began with an exclusive satellite event at MGI’s cutting-edge αLab in Hong Kong, followed by sessions at the company’s state-of-the-art global headquarters in Shenzhen, China. Attendees experienced a dynamic program featuring keynote speeches, the latest technology updates, product demonstrations, and an Eco-partner showcase. Renowned global leaders in the field shared insights, with a special focus on the transformative potential of omics technologies.
“We are thrilled to bring together some of the world’s leading life science researchers, academics, clinicians, and collaborators to exchange valuable insights,” said Duncan Yu, President of MGI, during his opening remarks. “Throughout our 8-year journey, innovation has been central to MGI. We continually strive to deliver cutting-edge technology that empowers diverse applications and expands multi-omics capabilities, unlocking new possibilities. We look forward to inspiring innovation and driving exciting developments in the future of omics.”
Sequencing Capabilities to Provide “SEQ ALL”
Dr. Rade Drmanac, Chief Scientific Officer of MGI, introduced the term “SEQ ALL” during his presentation, referring to MGI’s comprehensive capacity to offer a wide range of sequencing applications to meet diverse user needs.
“MGI provides a complete DCS lab for DNA, cell, and spatial omics. Together, these technologies define a new generation of MPS (MPS 2.0) and set a new standard in WGS (CompleteWGS). MGI is the only company offering the SEQ ALL portfolio, supporting all sequencing applications. MGI has it all.”
Powered by its advanced massively parallel sequencing (MPS) technology, DNBSEQ™, with key advantages in efficiency, accuracy, and cost-effectiveness, MGI offers T Series, G Series, and E Series genetic sequencers, with data throughput ranging from GB to TB, serving diverse user needs and scenarios. Earlier this year, MGI launched the Standard MPS 2.0 (SM2.0) upgrade for its DNBSEQ™ platforms, improving sequencing quality with an increased percentage of Q40 bases.
By leveraging its robust suite of technologies, MGI strengthens its position as a leading life sciences technology provider, offering versatile sequencing throughputs and read lengths, short-read and long-read sequencing, single-cell omics, and spatial omics—all under its “SEQ ALL” approach.
Expanding Multi-Omics Access Globally
Providing highly efficient whole workflow solutions for DNA omics, cell omics, spatial omics, and multi-omics, MGI is dedicated to empowering omics research to tackle complex biological challenges.
Multi-Omics
Last year, MGI launched the DCS Lab Initiative to facilitate global access to multi-omics capabilities. At the conference, MGI announced the successful establishment of 10 DCS labs across China, Germany, and Singapore, leveraging its unique ability to provide end-to-end solutions for both research and clinical translational applications.
MGI also launched DNBSEQ-G400RS FluoXpert, a multi-functional sequencer compatible with in vivo spatial protein detection. It supports a wide range of applications, including tumor classification, disease prognosis, and tissue microenvironment analysis.
Spatial Omics
As part of its commitment to providing users with the most accessible, comprehensive, and efficient spatial-temporal omics workflow solutions, MGI became an official distributor of a selection of STOmics-related products in July of this year. The Stereo-seq libraries are sequenced on MGI’s flagship DNBSEQ-G400RS and DNBSEQ-T7RS platforms, ensuring high-quality data output.
At the Future of Omics Conference, MGI introduced Stereo-seq Transcriptomics Solution v1.3 (Stereo-seq v1.3), an upgraded STOmics solution designed for fresh frozen samples. This version significantly improves the capture efficiency of whole transcriptome information at true single-cell resolution. The product is available for ordering starting in September. Previously, Stereo-seq OMNI, a revolutionary sequencing-based spatial transcriptomics solution compatible with multiple species, was released. Stereo-seq OMNI allows users to obtain spatial total RNA information from FFPE samples at single-cell resolution, diving deeper into molecular changes in precious clinical samples. Through its innovative "Random Probe" design, both total RNA and microbiome information can be detected on the same tissue slide.
Cell Omics
For cell omics, MGI offers a comprehensive platform that includes DNBelab C Series for single-cell research, encompassing storage, transport, sample preparation, labeling, library preparation, high-throughput sequencing, and data analysis.
At the conference, MGI introduced the DNBelab C series High-Throughput Single-Cell 5' RNA & V(D)J Library Preparation Kit. This kit can be used with the DNBelab C-TaiM4, a droplet generator previously released, to complete the droplet encapsulation process within 12 minutes. Combined with the DNBC4Tools analysis tool, it can process up to 20,000 cells per slide per run, completing single-cell 5' RNA, TCR, and BCR library preparation and data quality control analysis.
End-to-End Solutions
MGI is uniquely positioned to leverage its suite of automation platforms to develop comprehensive solutions that optimize every step of the process, delivering more impactful results. MGI has introduced solutions like low-pass sequencing for agriculture, eDNA for public health, and a human microbiome metagenomics sequencing package to enhance efficiency, accuracy, and research turnaround times, enabling researchers to focus on results rather than labor-intensive tasks.
At the conference, MGI also launched solutions for PopGen Omics. Population genetics examines genetic differences within and among populations, which can lead to clearer insights into disease prevention, risk prediction, and diagnosis. MGI’s PopOmics Sequencing Package offers a unique perspective by combining genomics, epigenomics, transcriptomics, and metagenomics into a comprehensive individual readout.
Equipped with multi-omics capabilities, MGI continues to offer a broad product lineup and end-to-end workflows, driving innovation in clinical genomics, population genomics, public health, animal and plant genomics, environmental genomics, and other applications.
Over the next three days of the Future of Omics conference, more than 60 speakers and 10 ecosystem partners from around the world will present their cutting-edge innovations and advancements in the field of omics. Together, they will exchange insights and collaborate on shaping the breakthroughs of tomorrow.
MGI’s Future of Omics Conference runs from 10 to 13 September 2024 in Shenzhen and Hong Kong. For more information, please visit: https://futureofomics.com/
For research use only. Not for use in diagnostic procedures.
Share this article :
Share
Jun 1, 2024
MGI Tech Shares New Data on Core DNEBSEQ Technology and Showcases Latest Sequencing Innovations at ESHG 2024
MGI showcased its latest innovations at the ESHG 2024, highlighting the upgraded StandardMPS 2.0 sequencing chemistry and unveiling the new DNBelab C-TaiM 4 Single-Cell Droplet Generator. European researchers presented advancements in diagnostics, population health, and more.
Apr 27, 2024
MGI Showcases New DNBSEQ-E25 Sequencer & Partners with ABL Diagnostics at ESCMID Global 2024
MGI introduced its portable DNBSEQ-E25 sequencer at ESCMID Global 2024, designed for mobile and efficient genomic sequencing with applications in infectious diseases. Additionally, MGI announced a partnership with ABL Diagnostics to integrate DeepChek® assays into its platforms, broadening NGS solutions for microbiology labs.
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).